Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0118 Transporter Info
Gene Name	SLC17A5
Transporter Name	Vesicular H(+)/Aspartate-glutamate cotransporter
Gene ID	26503
UniProt ID	Q9NRA2

Post-Translational Modification of This DT
Overview of SLC17A5 Modification Sites with Functional and Structural Information
Sequence	M R S P V R D L A R N D G E E S T D R T P L L P G A P R A E A A P V C C S A R Y N L A I L A F F G F F I V Y A L R V N L S V A L V D M V D S N T T L E D N R T S K A C P E H S A P I K V H H N Q T G K K Y Q W D A E T Q G W I L G S F F Y G Y I I T Q I P G G Y V A S K I G G K M L L G F G I L G T A V L T L F T P I A A D L G V G P L I V L R A L E G L G E G V T F P A M H A M W S S W A P P L E R S K L L S I S Y A G A Q L G T V I S L P L S G I I C Y Y M N W T Y V F Y F F G T I G I F W F L L W I W L V S D T P Q K H K R I S H Y E K E Y I L S S L R N Q L S S Q K S V P W V P I L K S L P L W A I V V A H F S Y N W T F Y T L L T L L P T Y M K E I L R F N V Q E N G F L S S L P Y L G S W L C M I L S G Q A A D N L R A K W N F S T L C V R R I F S L I G M I G P A V F L V A A G F I G C D Y S L A V A F L T I S T T L G G F C S S G F S I N H L D I A P S Y A G I L L G I T N T F A T I P G M V G P V I A K S L T P D N T V G E W Q T V F Y I A A A I N V F G A I F F T L F A K G E V Q N W A L N D H H G H R H
PTM type	X-N-glycosylation X-Phosphorylation X-Ubiquitination X: Amino Acid

N-glycosylation
Asparagine	3 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[1]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	71
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC17A5 Asparagine 71 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC17A5			[1]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	77
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC17A5 Asparagine 77 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC17A5			[1]
Role of PTM	Potential impacts
Modified Residue	Asparagine	Modified Location	95
Experimental Method	Co-Immunoprecipitation
Detailed Description	N-linked Glycosylation at SLC17A5 Asparagine 95 has the potential to affect its expression or activity.
Phosphorylation
Serine	4 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[2] , [3]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	3
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC17A5 Serine 3 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC17A5			[4] , [5]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	16
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC17A5 Serine 16 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC17A5			[6] , [7]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	268
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC17A5 Serine 268 has the potential to affect its expression or activity.
PTM Phenomenon 4	Have the potential to influence SLC17A5			[7] , [8]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	269
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC17A5 Serine 269 has the potential to affect its expression or activity.
Threonine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[4] , [5]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	17
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC17A5 Threonine 17 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC17A5			[9] , [10]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	20
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC17A5 Threonine 20 has the potential to affect its expression or activity.
Ubiquitination
Alanine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[11] , [12]
Role of PTM	Potential impacts
Modified Residue	Alanine	Modified Location	147
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Alanine 147 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC17A5			[13] , [14]
Role of PTM	Potential impacts
Modified Residue	Alanine	Modified Location	157
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Alanine 157 has the potential to affect its expression or activity.
Glutamicacid	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[13] , [14]
Role of PTM	Potential impacts
Modified Residue	Glutamicacid	Modified Location	262
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Glutamicacid 262 has the potential to affect its expression or activity.
Glutamine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[13]
Role of PTM	Potential impacts
Modified Residue	Glutamine	Modified Location	277
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Glutamine 277 has the potential to affect its expression or activity.
Glycine	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[13]
Role of PTM	Potential impacts
Modified Residue	Glycine	Modified Location	172
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Glycine 172 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC17A5			[13] , [14]
Role of PTM	Potential impacts
Modified Residue	Glycine	Modified Location	234
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Glycine 234 has the potential to affect its expression or activity.
Isoleucine	4 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[13]
Role of PTM	Potential impacts
Modified Residue	Isoleucine	Modified Location	201
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Isoleucine 201 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC17A5			[11] , [12]
Role of PTM	Potential impacts
Modified Residue	Isoleucine	Modified Location	212
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Isoleucine 212 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC17A5			[13]
Role of PTM	Potential impacts
Modified Residue	Isoleucine	Modified Location	285
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Isoleucine 285 has the potential to affect its expression or activity.
PTM Phenomenon 4	Have the potential to influence SLC17A5			[11] , [15]
Role of PTM	Potential impacts
Modified Residue	Isoleucine	Modified Location	319
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Isoleucine 319 has the potential to affect its expression or activity.
Leucine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[13] , [14]
Role of PTM	Potential impacts
Modified Residue	Leucine	Modified Location	270
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Leucine 270 has the potential to affect its expression or activity.
Lysine	4 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[11]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	132
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Lysine 132 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC17A5			[11]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	197
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Lysine 197 has the potential to affect its expression or activity.
PTM Phenomenon 3	Have the potential to influence SLC17A5			[13] , [14]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	263
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Lysine 263 has the potential to affect its expression or activity.
PTM Phenomenon 4	Have the potential to influence SLC17A5			[12] , [13]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	278
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Lysine 278 has the potential to affect its expression or activity.
Serine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[13]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	249
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Serine 249 has the potential to affect its expression or activity.
Threonine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[11] , [15]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	304
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Threonine 304 has the potential to affect its expression or activity.
Tryptophan	2 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[13] , [14]
Role of PTM	Potential impacts
Modified Residue	Tryptophan	Modified Location	186
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Tryptophan 186 has the potential to affect its expression or activity.
PTM Phenomenon 2	Have the potential to influence SLC17A5			[11]
Role of PTM	Potential impacts
Modified Residue	Tryptophan	Modified Location	246
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Tryptophan 246 has the potential to affect its expression or activity.
Tyrosine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon 1	Have the potential to influence SLC17A5			[11] , [12]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	261
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC17A5 Tyrosine 261 has the potential to affect its expression or activity.

References
1	dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: S17A5_HUMAN)
2	UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515.
3	A Methodological Assessment and Characterization of Genetically-Driven Variation in Three Human Phosphoproteomes. Sci Rep. 2018 Aug 14;8(1):12106.
4	Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase. EMBO J. 2018 Dec 14;37(24):e99559.
5	Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer. PLoS One. 2018 Oct 2;13(10):e0204658.
6	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
7	Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL. Blood Adv. 2018 Oct 9;2(19):2554-2567.
8	In-Depth Analyses of B Cell Signaling Through Tandem Mass Spectrometry of Phosphopeptides Enriched by PolyMAC. Int J Mass Spectrom. 2015 Feb 1;377:744-753.
9	Tip-Based Fractionation of Batch-Enriched Phosphopeptides Facilitates Easy and Robust Phosphoproteome Analysis. J Proteome Res. 2018 Jan 5;17(1):46-54.
10	Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells. Mol Cell Proteomics. 2018 Apr;17(4):550-564.
11	A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics. 2011 Oct;10(10):M111.013284.
12	Highly Multiplexed Quantitative Mass Spectrometry Analysis of Ubiquitylomes. Cell Syst. 2016 Oct 26;3(4):395-403.e4.
13	Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature. 2021 Jun;594(7862):246-252.
14	Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells. Proteomics. 2018 Aug;18(15):e1700388.
15	Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 2011 Oct 21;44(2):325-40.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence